Abstract

Inherited retinal degenerations (IRDs) are a diverse group of conditions that result in blindness in humans, dogs and cats. The spontaneous gene mutations that have arisen in the pet dog and cat population occur in the same genes as the analogous conditions in humans. Genetic studies that identify the causal mutations of IRDs in dogs and cats allow the development of DNA -based tests to eliminate the conditions from the pet population. They also offer the opportunity for development of translational therapeutic approaches. The dog and cat eye have many similarities to the human eye including in size and the presence of a central retinal region for high acuity vision. These similarities make them of particular value for testing of promising sight saving or restoring therapy. Gene augmentation therapies tested in dogs with IRDs have already led to human clinical trials for a variety of IRDs. Thus far this work has led to an approved commercially available therapy for an IRD that causes early-onset vision loss; Leber congenital amaurosis type 2. Approval of therapies for other IRDs developed in cats and dogs are likely in the future.